报价延迟最少15分钟:2025/07/20 19:34 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.864 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.74/-0.71
|
|
企业价值
59.20M
|
| 资产负债 |
|
每股账面净值
1.21
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
165.79K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 19:34 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
